LABELS · 02ee9cf4-c6d6-4239-854e-7c5976977456

Simponi

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-10-29
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ( 5.1 ) Discontinue SIMPONI if a patient develops a serious infection or sepsis ( 5.1 ) Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ( 5.1 ) Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member ( 5.2 ) SERIOUS INFECTIONS Patients treated with SIMPONI are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue SIMPONI if a patient develops a serious infection. Reported infections with TNF blockers, of which SIMPONI is a member, include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before SIMPONI use and during therapy. Initiate treatment for latent TB prior to SIMPONI use. Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. Consider the risks and benefits of treatment with SIMPONI prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMPONI, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1) ] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member [see Warnings and Precautions (5.2) ] .

Indications and usage: exact source text

1 INDICATIONS AND USAGE SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 ) 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Ulcerative Colitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis .

Full extracted label fields

application numbers

BLA125289

boxed warning exact

WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ( 5.1 ) Discontinue SIMPONI if a patient develops a serious infection or sepsis ( 5.1 ) Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ( 5.1 ) Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member ( 5.2 ) SERIOUS INFECTIONS Patients treated with SIMPONI are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue SIMPONI if a patient develops a serious infection. Reported infections with TNF blockers, of which SIMPONI is a member, include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before SIMPONI use and during therapy. Initiate treatment for latent TB prior to SIMPONI use. Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. Consider the risks and benefits of treatment with SIMPONI prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMPONI, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1) ] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member [see Warnings and Precautions (5.2) ] .

brand names

Simponi

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f86cb4a7-c358-4136-ae57-b32bda9bba00

generic names

GOLIMUMAB

02ee9cf4-c6d6-4239-854e-7c5976977456

indications and usage exact

1 INDICATIONS AND USAGE SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 ) 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Ulcerative Colitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis .

indications and usage tables exact

is original packager

true

manufacturer names

Janssen Biotech, Inc.

matched search terms

tumor

package ndcs

57894-070-01
57894-070-02
57894-070-90
57894-070-89
57894-071-01
57894-071-02
57894-071-90
57894-071-89

product ndcs

57894-070
57894-071

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1.4 ) 10/2025 Dosage and Administration ( 2.1 , 2.3 , 2.4 ) 10/2025 Warnings and Precautions ( 5.11 ) 10/2025

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

848160
848164
1482813
1482814
1653142
1653144
1653165
1653166

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 421
end exclusive: true
exact text: 1 INDICATIONS AND USAGE SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients wei
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 0

current approval status

not_reconciled

duplicate text group

dup-85801e54ec27e4bc8899

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-7589427f71c03fc35d70

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 32

qualifier mentions

context exact
crosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA
kind
age
polarity
not_inferred
span
end
119
end exclusive
true
exact text
adult patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
105
context exact
verely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 )
kind
biomarker
polarity
not_inferred
span
end
217
end exclusive
true
exact text
methotrexate ( 1
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
201
context exact
ith moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 )
kind
regimen
polarity
not_inferred
span
end
217
end exclusive
true
exact text
in combination with methotrexate ( 1
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
181

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 221
end exclusive: true
exact text: 1 INDICATIONS AND USAGE SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 )
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 525
end exclusive: true
exact text: E SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 ) 1.1 Rheumatoid A
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 22

current approval status

not_reconciled

duplicate text group

dup-7949a8c18ec94e11360e

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-e34eb6d4ae23d371b3ef

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 32

qualifier mentions

context exact
adult patients with active psoriatic arthritis (PsA) alone, or in combinat
kind
age
polarity
not_inferred
span
end
236
end exclusive
true
exact text
adult patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
222
context exact
ive psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 )
kind
biomarker
polarity
not_inferred
span
end
321
end exclusive
true
exact text
methotrexate ( 1
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
305
context exact
lt patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 )
kind
regimen
polarity
not_inferred
span
end
321
end exclusive
true
exact text
in combination with methotrexate ( 1
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
285

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 325
end exclusive: true
exact text: adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 )
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 222

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 3 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 588
end exclusive: true
exact text: oderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 ) 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicate
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 126

current approval status

not_reconciled

duplicate text group

dup-b7d383d7fd4e87d02365

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-97a0a266dde3c25794a9

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 32

qualifier mentions

context exact
adult patients with active ankylosing spondylitis (AS) ( 1.3 )
kind
age
polarity
not_inferred
span
end
340
end exclusive
true
exact text
adult patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
326

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 388
end exclusive: true
exact text: adult patients with active ankylosing spondylitis (AS) ( 1.3 )
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 326

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 708
end exclusive: true
exact text: nation with methotrexate ( 1.1 ) adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 ) 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis S
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 189

current approval status

not_reconciled

duplicate text group

dup-cc1ab457e98da4446028

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-8ad3f761f2c9e099760a

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 82
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 32

qualifier mentions

context exact
adult and pediatric patients weighing at least 15 kg with moderat
kind
age
polarity
not_inferred
span
end
394
end exclusive
true
exact text
adult
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
389
context exact
adult and pediatric patients weighing at least 15 kg with moderately to severely active
kind
age
polarity
not_inferred
span
end
417
end exclusive
true
exact text
pediatric patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
399

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 508
end exclusive: true
exact text: adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 )
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 389

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 882
end exclusive: true
exact text: otrexate ( 1.2 ) adult patients with active ankylosing spondylitis (AS) ( 1.3 ) adult and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC) ( 1.4 ) 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis SIMPONI is ind
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 309

current approval status

not_reconciled

duplicate text group

dup-9a74f668d5ac14e02f83

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-274c4f746a366db0a9bc

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 589
end exclusive: true
exact text: is indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 577

qualifier mentions

context exact
nation with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
kind
age
polarity
not_inferred
span
end
625
end exclusive
true
exact text
adult patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
611
context exact
1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with mode
kind
biomarker
polarity
not_inferred
span
end
575
end exclusive
true
exact text
methotrexate
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
563
context exact
1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
kind
regimen
polarity
not_inferred
span
end
681
end exclusive
true
exact text
in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
543

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 682
end exclusive: true
exact text: 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 509

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1040
end exclusive: true
exact text: tive colitis (UC) ( 1.4 ) 1.1 Rheumatoid Arthritis SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Ulcerative Colitis SIMPONI is indicated for the treatment of adults and ped
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 483

current approval status

not_reconciled

duplicate text group

dup-1810d3e414424dae3d54

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-066b3f56b63327911c7f

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 771
end exclusive: true
exact text: is indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 759

qualifier mentions

context exact
nation with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis.
kind
age
polarity
not_inferred
span
end
807
end exclusive
true
exact text
adult patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
793
context exact
2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with acti
kind
biomarker
polarity
not_inferred
span
end
757
end exclusive
true
exact text
methotrexate
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
745
context exact
1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis.
kind
regimen
polarity
not_inferred
span
end
839
end exclusive
true
exact text
in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
725

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 840
end exclusive: true
exact text: 1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis.
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 683

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1135
end exclusive: true
exact text: to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Ulcerative Colitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis .
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 641

current approval status

not_reconciled

duplicate text group

dup-9e4ba3cf62d0fe7c966e

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-c88b9981eea283cae0c1

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 888
end exclusive: true
exact text: is indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 876

qualifier mentions

context exact
osing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis.
kind
age
polarity
not_inferred
span
end
924
end exclusive
true
exact text
adult patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
910

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 960
end exclusive: true
exact text: 1.3 Ankylosing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis.
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 841

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

BLA125289

brand names

Simponi

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1135
end exclusive: true
exact text: indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Ulcerative Colitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis .
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 761

current approval status

not_reconciled

duplicate text group

dup-10935b8241ad2576e77b

extraction review status

automated_candidate_pending_source_review

generic names

GOLIMUMAB

ind-span-2a094daa238fee7f1f08

label id

02ee9cf4-c6d6-4239-854e-7c5976977456

positive predicate support span

end: 1004
end exclusive: true
exact text: is indicated
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 992

qualifier mentions

context exact
lcerative Colitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderat
kind
age
polarity
not_inferred
span
end
1032
end exclusive
true
exact text
adults
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
1026
context exact
olitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active
kind
age
polarity
not_inferred
span
end
1055
end exclusive
true
exact text
pediatric patients
label id
02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start
1037

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1135
end exclusive: true
exact text: 1.4 Ulcerative Colitis SIMPONI is indicated for the treatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis .
label id: 02ee9cf4-c6d6-4239-854e-7c5976977456
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 17837c52c07f86e85e84ae74b4224fa6ff5be9903a912ed25b0a477179130879
start: 961

source url

https://api.fda.gov/drug/label.json?search=id%3A%2202ee9cf4-c6d6-4239-854e-7c5976977456%22

spl effective date

2025-10-29

spl set id

f86cb4a7-c358-4136-ae57-b32bda9bba00

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice